🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. PLX-200

    Polaryx Therapeutics

    Juvenile Neuronal Ceroid Lipofuscinosis

    phase 3 small molecule active

    1 trial

  2. PRAX-628, PRAX-628, PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures.

    phase 3 small molecule active

    1 trial

  3. PREDNISOLONE, CORTISONE ACETATE, FLUDROCORTISONE, Gohibic, TRIAMCINOLONE, PREDNISONE, DEXAMETHASONE, HYDROCORTISONE, METHYLPREDNISOLONE, IFX-1 placebo is formulated as PBS (150 mM sodium chloride, 10 mM sodium phosphate, pH 7.0) with 0.05% polysorbate 80. IFX-1 placebo is diluted in sterile 0.9% sodium chloride to the required concentration and volume. This diluent is a commercial product not accompanying IFX-1 placebo., BETAMETHASONE

    InflaRx GmbH

    ulcerative pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  4. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Active Ulcerative Colitis (UC) or Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  5. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Moderately to severely active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  6. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion, BUDESONIDE

    Takeda

    Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  7. PREDNISONE, PREDNISONE, SODIUM CHLORIDE, RITUXIMAB

    Fondazione Telethon ETS

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  8. PREDNISONE, SRP-9003, PREDNISONE, PREDNISONE

    Sarepta Therapeutics

    Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglycanopathy

    phase 3 small molecule active

    1 trial

  9. PRIDOPIDINE, Pridopidine placebo

    Ferrer Internacional S.A.

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  10. PRO 2000/5

    United Therapeutics Europe Ltd

    HIV Infections

    phase 3 small molecule completed

    1 trial

  11. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  12. PRX-102

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 small molecule completed

    2 trials

  13. PRX-102 (pegunigalsidase alfa)

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    3 trials

  14. PTC299

    PTC THERAPEUTICS, INC.

    Pneumonia

    phase 3 small molecule terminated

    1 trial

  15. PTC923

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    2 trials

  16. PTC923, Kuvan 100 mg soluble tablets, PTC923

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  17. PTC923, PTC923

    PTC THERAPEUTICS, INC.

    Metabolic Disorders - Phenylketonuria

    phase 3 small molecule active

    1 trial

  18. PTX-022

    PALVELLA THERAPEUTICS, INC.

    Pachyonychia Congenita

    phase 3 small molecule active

    3 trials

  19. Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE

    Olema Pharmaceuticals

    ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy

    phase 3 small molecule active

    1 trial

  21. Palliative Chemotherapy

    Sun Yat-sen University

    Colorectal Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  22. Panzyga 100 mg/ml Infusionslösung, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung

    Maze Therapeutics

    Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.

    phase 3 small molecule active

    1 trial

  23. Pegtibatinase

    Travere Therapeutics

    Homocystinuria

    phase 3 small molecule active

    3 trials

  24. Pegtibatinase, 0.9 % sodium chloride saline solution (NaCL)

    Travere Therapeutics

    Classical Homocystinuria

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources